APA (7th ed.) Citation

Raab, M., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., . . . Chatterjee, M. (2020). Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1-2a trial. The lancet. Haematology, 7(5), . https://doi.org/10.1016/S2352-3026(19)30249-2

Chicago Style (17th ed.) Citation

Raab, Marc-Steffen, et al. "Y MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma: A First-in-human, Multicentre, Phase 1-2a Trial." The Lancet. Haematology 7, no. 5 (2020). https://doi.org/10.1016/S2352-3026(19)30249-2.

MLA (9th ed.) Citation

Raab, Marc-Steffen, et al. "Y MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma: A First-in-human, Multicentre, Phase 1-2a Trial." The Lancet. Haematology, vol. 7, no. 5, 2020, https://doi.org/10.1016/S2352-3026(19)30249-2.